Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679092 | 1.00 | TSHR (0.39) | TSHRSMN1; SMN2FAAHPRSS1PRSS2 | |
| SCHEMBL1476157 | 0.93 | FAAH (0.39) | TSHRSMN1; SMN2FAAHPRSS1PRSS2 | |
| SCHEMBL7914149 | 0.93 | FAAH (0.39) | TSHRSMN1; SMN2FAAHPRSS1PRSS2 | |
| SCHEMBL561475 | 0.93 | FAAH (0.39) | TSHRSMN1; SMN2FAAHPRSS1PRSS2 | |
| SCHEMBL5078707 | 0.93 | FAAH (0.39) | TSHRSMN1; SMN2FAAHPRSS1PRSS2 | |
| SCHEMBL2283421 | 0.93 | FAAH (0.39) | TSHRSMN1; SMN2FAAHPRSS1PRSS2 | |
| SCHEMBL7102917 | 0.93 | FAAH (0.39) | TSHRSMN1; SMN2FAAHPRSS1PRSS2 | |
| SCHEMBL7038440 | 0.89 | CA12 (0.39) | TSHRSMN1; SMN2CYP2D6TDP1CA2 | |
| Sulfuric Acid SCHEMBL5798237 | 0.89 | TSHR (0.44) | TSHRSMN1; SMN2POLBCYP2D6TDP1 | |
| SCHEMBL1477345 | 0.85 | ALDH1A1 (0.40) | TDP1CA2ALDH1A1CA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2196462-B1 | Polymerizable compound, lactone-containing compound, method for manufacturing lactone-containing compound and polymer compound obtained by polymerizing the polymerizable compound | FUJIFILM CORP (JP) | 2011-09-28 | — | — | EP | disclosed |
| US-20100152400-A1 | POLYMERIZABLE COMPOUND, LACTONE-CONTAINING COMPOUND, METHOD FOR MANUFACTURING LACTONE-CONTAINING COMPOUND AND POLYMER COMPOUND OBTAINED BY POLYMERIZING THE POLYMERIZABLE COMPOUND | FUJIFILM CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-2196462-A1 | Polymerizable compound, lactone-containing compound, method for manufacturing lactone-containing compound and polymer compound obtained by polymerizing the polymerizable compound | Fujifilm Corporation (JP) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152400-A1 | POLYMERIZABLE COMPOUND, LACTONE-CONTAINING COMPOUND, METHOD FOR MANUFACTURING LACTONE-CONTAINING COMPOUND AND POLYMER COMPOUND OBTAINED BY POLYMERIZING THE POLYMERIZABLE COMPOUND | CCNO, DCXR, FGB | TSHR 3045/4885SMN1; SMN2 4396/4885FAAH 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.